Abstract 434P
Background
A number of provincial online treatment guidelines/protocols exist in Canada, which differ in the information contained and the ease of use. Currently there is no national evidence-based, consensus-driven cancer treatment protocol for use at the point of care. The aim of such a resource would be to support Medical Oncologists (MOs) in the delivery of cancer treatment at the clinic interface and potentially improve patient outcomes by reducing treatment variation across Canada.
Methods
The study was conducted in two stages. Available provincial cancer treatment protocols were evaluated with regards to: content for chemotherapy, immunotherapy, ease of use, toxicity, dosing recommendations, reference studies. Canadian MOs were invited to participate in an anonymous survey distributed through the Canadian Association of Medical Oncologists. The assessment included: current online resources (OR) used, information provided, ease of use, relevance to point of care use, need for a national Canadian resource. MOs were asked to review a comparator Pan-Australian OR.
Results
40/327 responded: 28% BC, 26% ON and the rest from other provinces. 82%, 54% and 23% respectively used the BC and ON and other provincial ORs. 50% used ≥2 websites. 62% found the website of choice easy to use, 33% felt it had updated immune therapy information and 26% felt it was updated regularly. The OR used met the MO need for dose/scheduling in 87.5% cases but only 50% and 37.5% cases for AEs and reference information respectively. Criteria evaluated in the ORs included: dosing, toxicity modification, AEs, monitoring, references and other criteria. 95% of MOs felt that a single portal aimed at point of care for Canadian MOs would be of value. 64% felt that the international comparator was better than the current OR being used.
Conclusions
There is variation in the current Canadian OR used by MOs in Canada with a need for national evidence-based, cancer treatment protocols/information for use at the point of care. To develop such a Pan-Canadian website resource, further analysis and infrastructure is required. Such a resource would potentially reduce treatment variability and augment quality of care delivered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session